为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌术后细胞因子诱导的杀伤细胞和树突状细胞辅助免疫治疗：系统评价和 meta 分析
英文原题：Post-operative adjuvant immunotherapy with cytokine-induced killer and dendritic cells for hepatocellular carcinoma: A systematic review and meta-analysis.
查看英文原题
Post-operative adjuvant immunotherapy with cytokine-induced killer and dendritic cells for hepatocellular carcinoma: A systematic review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- Guo H、Meng Y、Peng J、Yang X
- 第一作者单位
- The First Clinical Medicine College, Gansu University of Chinese Medicine, Lanzhou, 730000, Gansu Province, China.China
- 通讯作者单位
- Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou, 730000, Gansu Province, China; Peoples Clinical Medicine College, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Gansu Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China; Gansu Research Center of Prevention and Control Project for Digestive Oncology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China. Electronic address: yangxjmd@aliyun.com.China
- 文献类型
- 荟萃分析 · 系统综述 · 读者来信
- 期刊
- Asian journal of surgery2023 Jun
- 原文标识
- PubMed 36599723 · DOI 10.1016/j.asjsur.2022.12.049